Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces four abstract presentations at the AUA 2025, highlighting the benefits of Blue Light Cystoscopy (BLC®), notably its impact on management ...

Among patients with non-muscle-invasive bladder cancer (NMIBC), neoadjuvant treatment with mitomycin C prior to transurethral ...

TAR-200 demonstrated a high disease-free survival and bladder preservation rates in BCG-unresponsive, high-risk ...

Oncologists at AUA 2025 share promising data, including sasanlimab, cretostimogene grenadenorepvec, and TAR-200 in NMIBC.

UroGen Pharma reports strong long-term data for Jelmyto and UGN-102 in cancer studies and shares promising early results for ...

The targeted drug release device TAR-200 shows promising response and disease-free survival rates in specific populations of ...

Pfizer has linked its PD-1 inhibitor to a 32% reduction in the risk of disease-related events in a phase 3 bladder cancer ...

It can take years for prostate cancer to turn castration-resistant, when cancer cells stop responding to hormonal therapy.

Johnson & Johnson (J&J) has reported more data supporting the efficacy of its intravesical drug release system TAR-200 in ...

US-based pharmaceutical company Pfizer has reported positive results from a Phase III trial of sasanlimab and Bacillus ...